03:27:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Kvartalsrapport 2017-Q1
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2021-02-17 08:00:17
Oslo, Norway (17 February 2021)

Followed by a very strong first nine month of 2020, NattoPharma increased
revenues in the fourth quarter by 62%, bringing the FY growth to 69% compared to
the same period in 2019. The total revenue for 2020 ended up at NOK 214.5
million passing the NOK 200 million for the first in the history of the company.
FY Adjusted EBITDA came in at NOK 37.3 million equal to a margin of 17.4%.

Performance highlights for Q4 2020 (Q4 2019 in brackets)

· Operating revenue of NOK 62.3m (NOK 38.5m)
· Adjusted EBITDA of NOK 14.4m (NOK 2.2m) / Adjusted EBITDA% of 23.1% (3.0%)
· Adjusted Total OpeX as % of Revenue 21.2% (29.7%)

Performance highlights for FY 2020 (FY 2019 in brackets)

· Operating revenue of NOK 214.5m (NOK 127.1m)
· Adjusted EBITDA of NOK 37.3m (NOK 8.2m) / Adjusted EBITDA% of 17.4% (6.5%)
· Adjusted Total OpeX as % of Revenue 25.2% (33.6%)
· Cash flow from Operating Activities of NOK 25.4m (NOK 6.4m)
· Inventory balance of NOK 49.4 (NOK 33.7)

CEO, Kjetil Ramsøy:

"We finished 2020 with strong growth delivering the best quarter in our history,
set­ting a new revenue record for a single quarter of NOK 62.3 million, and
ending the year well in line with the previous guiding with full-year revenue of
NOK 214.5 mil­lion. The group performance in 2020 has been outstanding - driven
by a great team and strong relationships with partners on both the customer and
supplier side."

Strategic Review Process

On Monday February 15th, 2021, NattoPharma announced that it has entered into a
Transaction Agreement with Com­pagnie des Levures Lesaffre where­by Lesaffre
announced that they will launch an offer to acquire all outstanding shares of
NattoPharma through a voluntary cash offer of NOK 30 per share. An offer that is
recommended by the full Board of Directors of NattoPharma.

On the same day NattoPharma announced its intention to launch a cash tender
offer to acquire 100% of the shares of Kaydence Pharma AS through a voluntary
cash offer of NOK 5 per share. The completion of this offer is subject to
Lesaffre completing the offer to acquire all NattoPharma shares.

For further details we refer to the separate press releases from 15 February
2021 available through our website at www.nattopharma.com.

Guiding

Going into 2021, we see continued healthy development in the market and our
expectation for 2021 compared to 2020 is a growth in the range from 20% to 30%
growth year on year. Our Adj. EBITDA is expected to be in between 17% and 22% of
revenue.

Please find enclosed the NattoPharma Group Q4 2020 Report.



For more information, please contact:

Robert Schrama, CFO, NattoPharma, robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.